Merck & Co reported lower than expected third quarter revenue, hurt by sharply lower sales of its Gardasil vaccine against cervical cancer, but cost cuts enabled the company to beat earnings forecasts.
via NYT > Business Day http://ift.tt/1nJiqUz
via WordPress http://ift.tt/1stMYoN
No comments:
Post a Comment